2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N8518
    Malabaricone C 63335-25-1 ≥99.0%
    Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells.
    Malabaricone C
  • HY-108738
    Daclizumab 152923-56-3 ≥99.0%
    Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research.
    Daclizumab
  • HY-111673
    8-CPT-Cyclic AMP sodium 93882-12-3 ≥99.0%
    8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC50 of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC50Epac and is a potent Epac activator.
    8-CPT-Cyclic AMP sodium
  • HY-113332
    Myristoleic acid 544-64-9 ≥98.0%
    Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.
    Myristoleic acid
  • HY-13662B
    (R)-Lansoprazole 138530-94-6 98.91%
    (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    (R)-Lansoprazole
  • HY-141550
    BPK-25 2305052-86-0 99.92%
    BPK-25, an active acrylamide, promotes degradation of nucleosome remodeling and deacetylation (NuRD) complex proteins by a post-translational mechanism involving covalent protein engagement. BPK-25 inhibits TMEM173 activation by the cyclic dinucleotide ligand cGAMP.
    BPK-25
  • HY-163731
    EGR-1-IN-1
    EGR-1-IN-1 (IT25) is an inhibitor targeting EGR-1, with IC50 of 1.86 μM. EGR-1-IN-1 can be used in the research of inflammatory skin diseases.
    EGR-1-IN-1
  • HY-A0203A
    Pentosan Polysulfate (Sodium) (W/W 43%) 140207-93-8
    Pentosan Polysulfate Sodium is an orally bioavailable, semi-synthetic medication with anti-inflammatory and pro-chondrogenic properties. Pentosan Polysulfate Sodium also is a potent and selective anti-HIV agent. Pentosan Polysulfate Sodium is used for the treatment of interstitial cystitis.
    Pentosan Polysulfate (Sodium) (W/W 43%)
  • HY-100807S
    Quinolinic acid-d3 138946-42-6 ≥99.0%
    Quinolinic acid-d3 is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].
    Quinolinic acid-d3
  • HY-W004260
    Arachidic acid 506-30-9
    Arachidonic acid (Icosanoic acid), an orally active long-chain fatty acid, is present in all mammalian cells, typically esterified to membrane phospholipids, and is one of the most abundant saturated fatty acids present in human tissue. Moreover, Arachidonic acid is an important mediator of inflammation.
    Arachidic acid
  • HY-101027
    GSK 4027 2079896-25-4 98.22%
    GSK 4027 is a chemical probe for the PCAF/GCN5 bromodomain with an pIC50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
    GSK 4027
  • HY-101093
    CA-170 1673534-76-3 99.39%
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes.
    CA-170
  • HY-108896
    Icatibant acetate 138614-30-9 99.85%
    Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with an IC50 and Ki of 1.07 nM and 0.798 nM respectively.
    Icatibant acetate
  • HY-11068
    SB 239063 193551-21-2
    SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD.
    SB 239063
  • HY-13060
    ACHP Hydrochloride 406209-26-5 ≥99.0%
    ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective IKK-β inhibitor with an IC50 of 8.5 nM.
    ACHP Hydrochloride
  • HY-14908
    Vidofludimus 717824-30-1 99.14%
    Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR.
    Vidofludimus
  • HY-115688
    TXNIP-IN-1 1268955-50-5
    TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease.
    TXNIP-IN-1
  • HY-A0106
    Levamisole 14769-73-4 99.96%
    Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC50=300 μM) and α3β4 (EC50=100 μM) subtype of nAChRs. Orally active.
    Levamisole
  • HY-124290
    Carotegrast methyl 401905-67-7 98.89%
    Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice.
    Carotegrast methyl
  • HY-12743A
    K-7174 dihydrochloride 191089-60-8 98.60%
    K-7174 dihydrochloride is an orally active proteasome and GATA inhibitor. K-7174 dihydrochloride is a cell adhesion inhibitor. K-7174 dihydrochloride induces cell apoptosis. K-7174 dihydrochloride shows antitumor activities, it can be used for the research of cancer.
    K-7174 dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity